Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immatics N.V.IMTX · Entity 4718 | Director | June 16, 2026 | June 18, 2026 |
| Q32 Bio Inc.FIXX · Entity 5594 | Director | June 14, 2023 | June 15, 2023 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | Director | June 04, 2026 | June 05, 2026 |
| Tectonic Therapeutic, Inc.TECX · Entity 5328 | Director · Chief Executive Officer | September 25, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immatics N.V.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.09 · Expires 2036-06-15 | Direct | 48,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 48,000 · Balance 48,000 F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026.
Q32 Bio Inc.
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2033-06-14 | Direct | 23,000 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 23,000 · Balance 23,000 F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.
Sana Biotechnology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-03 | Direct | 90,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Tectonic Therapeutic, Inc.
Report date September 25, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 309,078 |
Reported balance
After 2026-09-25 transaction · row 1
1 source rowRow 1 · 2026-09-25 · Tax withholding · Disposed 1,545 · Balance 309,078 F1: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 127,030 |
Reported balance
Holding disclosure · report date 2026-09-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 127,030 F2: These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025.
F2: These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-20 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-11-20 · Grant · Acquired 4,298 · Balance 11,479 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 2 · 2019-11-20 · Grant · Acquired 8,927 · Balance 20,406 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 3 · 2019-11-20 · Grant · Acquired 24,209 · Balance 44,615 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 4 · 2019-11-20 · Disposition to issuer · Disposed 44,615 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.61 · Expires 2028-11-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 42,500 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: The option was fully exercisable |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 23,807 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 37,660 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F3: The option was fully exercisable
F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2026 Filed Oct 3, 2026 00:57 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Tax withholdingCommon Stock | 1,545 | $23.67 | $36,570.15 |
DisclosureSEC source: 0001757533-26-000016 · form4-10022026_081054.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,078 F1 · shares: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 20:45 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 69,250 | $0.00 Strike: $29.92 | $0.00 |
DisclosureSEC source: 0001757533-26-000014 · form4-09082026_040901.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,250 Underlying: Common Stock · 69,250 shares Expires 2036-09-02 F1 · derivative.exercise_date: 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 20, 2026 Filed Jun 23, 2026 21:52 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Tax withholdingCommon Stock | 924 | $30.34 | $28,034.16 |
DisclosureSEC source: 0001757533-26-000012 · form4-06232026_090656.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,623 F1 · shares: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on December 4, 2024. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:49 UTC | Immatics N.V. IMTX · Entity 4718 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000950103-26-009244 · ownership.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2036-06-15 F1 · derivative.exercise_date: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:38 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001757533-26-000011 · primarydocument.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:47 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 69,250 | $0.00 Strike: $27.41 | $0.00 |
DisclosureSEC source: 0001757533-26-000009 · form4-03052026_100320.xml · derivative · entry 3 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,250 Underlying: Common Stock · 69,250 shares Expires 2036-03-03 F3 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:47 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 76,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001757533-26-000009 · form4-03052026_100320.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,547 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:15 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | PurchaseCommon Stock | 2,500 | $21.10 | $52,750.00 |
DisclosureSEC source: 0001757533-26-000005 · form4-02122026_040204.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,547 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.02 to $21.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2026 Filed Mar 5, 2026 21:30 UTC Amendment | Tectonic Therapeutic, Inc. TECX · Entity 5328 | PurchaseCommon Stock | 2,500 | $21.10 | $52,750.00 |
DisclosureSEC source: 0001757533-26-000008 · form4a-03052026_040323.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 127,030 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.02 to $21.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 04, 2026 Filed Feb 10, 2026 21:07 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Tax withholdingCommon Stock | 4,104 | $23.22 | $95,294.88 |
DisclosureSEC source: 0001757533-26-000004 · form4-02102026_090253.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,047 F1 · shares: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:02 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,966 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0001757533-26-000002 · form4-01052026_100128.xml · derivative · entry 3 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,957 Underlying: Common Stock · 10,966 shares Expires 2031-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Received in exchange for a stock option to acquire 63,478 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/xslF345X05/form4-06242024_080648.xml F2 · derivative.exercise_date: The shares subject to the option vested as follows: (i) 4,079 shares on June 30, 2024; (ii) 4,078 shares on July 31, 2024, (iii) 4,078 shares on August 31, 2024, (iv) 4,079 shares on September 30, 2024, (v) 4,078 shares on October 31, 2024, (vi) 1,297 shares on November 30, 2024, (vii) 4,078 shares on January 31, 2025, (viii) 4,078 shares on February 28, 2025 and (iv) 4,078 shares on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:02 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionCommon Stock | 10,966 | $2.38 | $26,099.08 |
DisclosureSEC source: 0001757533-26-000002 · form4-01052026_100128.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 21:00 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 26,710 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0001757533-25-000004 · form4-09292025_050901.xml · derivative · entry 3 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,710 Underlying: Common Stock · 26,710 shares Expires 2035-09-24 F3 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 21:00 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 14,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001757533-25-000004 · form4-09292025_050901.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,185 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of September 25, 2026, September 25, 2027 and September 25, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:55 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Tax withholdingCommon Stock | 859 | $19.81 | $17,016.79 |
DisclosureSEC source: 0001415889-25-018106 · form4-06242025_080636.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,485 F1 · shares: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units granted on December 4, 2024. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:39 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-25-004643 · primarydocument.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:05 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 101,953 | $0.00 Strike: $48.01 | $0.00 |
DisclosureSEC source: 0001415889-25-003225 · form4-02062025_040201.xml · derivative · entry 3 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,953 Underlying: Common Stock · 101,953 shares Expires 2035-02-03 F3 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on March 4, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:05 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 36,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003225 · form4-02062025_040201.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,344 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of February 4, 2026, February 4, 2027 and February 4, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 22:19 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $51.28 | $0.00 |
DisclosureSEC source: 0001415889-24-028516 · form4-12062024_101244.xml · derivative · entry 3 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2034-12-03 F4 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on June 20, 2025 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 22:19 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 11,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028516 · form4-12062024_101244.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,297 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 4 equal annual installments with the first installment vesting on June 20, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · balance_after: 4,079 of these shares are subject to vesting and a repurchase right in favor of the Issuer. Such repurchase right will lapse on December 31, 2024 so long as the Reporting Person continues to provide service to the Issuer on such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 289,600 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017952 · form4-06242024_080648.xml · derivative · entry 5 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,600 Underlying: Common Stock · 289,600 shares Expires 2034-06-19 F10 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on June 20, 2025 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 23,380 | Not disclosed Strike: $5.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-017952 · form4-06242024_080648.xml · derivative · entry 4 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,380 Underlying: Common Stock · 23,380 shares Expires 2033-11-30 F5 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F5 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F5 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F9 · price: Received in exchange for a stock option to acquire 43,750 shares of Tectonic common stock pursuant to the Merger Agreement. F8 · derivative.exercise_date: The shares subject to the option vest in 42 equal monthly installments beginning on July 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F5 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 33,923 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-017952 · form4-06242024_080648.xml · derivative · entry 3 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,923 Underlying: Common Stock · 33,923 shares Expires 2031-06-27 F5 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F5 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F5 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F7 · price: Received in exchange for a stock option to acquire 63,478 shares of Tectonic common stock pursuant to the Merger Agreement. F6 · derivative.exercise_date: The shares subject to the option vest as follows: (i) 4,079 shares on June 30, 2024; (ii) 4,078 shares on July 31, 2024, (iii) 4,078 shares on August 31, 2024, (iv) 4,079 shares on September 30, 2024, (v) 4,078 shares on October 31, 2024, (vi) 1,297 shares on November 30, 2024, (vii) 4,078 shares on January 31, 2025, (viii) 4,078 shares on February 28, 2025 and (iv) 4,078 shares on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F5 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 124,530 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-017952 · form4-06242024_080648.xml · nonDerivative · entry 2 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 124,530 F3 · price: Received in exchange for 233,019 shares of common stock of Tectonic on the same terms and conditions as set forth in footnote (2) herein. F4 · ownership.nature: These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 166,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-017952 · form4-06242024_080648.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,580 F1 · shares: Certain of these shares are subject to vesting and a repurchase right in favor of the Issuer, as follows: (i) 2,256 shares on July 10, 2024, (ii) 2,256 shares on August 10, 2024, (iii) 2,781 shares on November 30, 2024, and (iv) 4,079 shares on December 31, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · price: Received in exchange for 311,703 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. F1 · balance_after: Certain of these shares are subject to vesting and a repurchase right in favor of the Issuer, as follows: (i) 2,256 shares on July 10, 2024, (ii) 2,256 shares on August 10, 2024, (iii) 2,781 shares on November 30, 2024, and (iv) 4,079 shares on December 31, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:22 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 54,278 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-004841 · primarydocument.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,278 Underlying: Common Stock · 54,278 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 06, 2024 Filed Jul 15, 2024 20:11 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-005719 · primarydocument.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-06-05 F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 22:04 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-23-028379 · ownership.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:34 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005031 · primarydocument.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000899243-22-023064 · doc4.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:39 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001562180-22-004946 · primarydocument.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:40 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0000899243-21-025331 · doc4.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 17, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005067 · doc4.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-02-02 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. Read SEC document |
| February 03, 2021 Filed Feb 18, 2021 23:59 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 11,795 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007195 · doc4a.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,795 Underlying: Common Stock · 11,795 shares Expires 2031-02-02 F1 · shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F2 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0000899243-20-016398 · doc4.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 10, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 37,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001372 · form4-11222019_071151.xml · derivative · entry 7 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,660 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 23,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001372 · form4-11222019_071151.xml · derivative · entry 6 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,807 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $75.61 | $0.00 |
DisclosureSEC source: 0001415889-19-001372 · form4-11222019_071151.xml · derivative · entry 5 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,500 shares Expires 2028-11-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: The option was fully exercisable F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 44,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001372 · form4-11222019_071151.xml · nonDerivative · entry 4 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 24,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001372 · form4-11222019_071151.xml · nonDerivative · entry 3 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,615 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 8,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001372 · form4-11222019_071151.xml · nonDerivative · entry 2 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,406 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 4,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001372 · form4-11222019_071151.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,479 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 11,903 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001258 · form4-11042019_041119.xml · derivative · entry 3 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,807 Underlying: Common Stock · 11,903 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2014 Equity Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock. F4 · balance_after: The remainder of the restricted stock units will vest in two installments as follows: 11,903 shares on November 1,2020 and 11,904 shares on November 1, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 4,722 | $108.53 | $512,478.66 |
DisclosureSEC source: 0001415889-19-001258 · form4-11042019_041119.xml · nonDerivative · entry 2 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,181 Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 11,903 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001258 · form4-11042019_041119.xml · nonDerivative · entry 1 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 21:36 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 31,160 | $0.00 Strike: $19.25 | $0.00 |
DisclosureSEC source: 0000899243-19-019625 · doc4.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,160 Underlying: Common Stock · 31,160 shares Expires 2029-07-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in three substantially equal annual installments following the date of grant, subject to the Non-Employee Director continuing service on the Board as a Non-Employee Director through each such vesting date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 37,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000250 · form4-03052019_040316.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,660 Underlying: Common Stock · 37,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 35,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001581 · form4-11022018_041101.xml · derivative · entry 2 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,710 Underlying: Common Stock · 35,710 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2014 Equity Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments commencing on November 1, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments commencing on November 1, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $75.61 | $0.00 |
DisclosureSEC source: 0001415889-18-001581 · form4-11022018_041101.xml · derivative · entry 1 REICIN ALISE · CIK 0001757533 · PRES., GLOBAL CLINICAL DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2028-11-01 F2 · price: The option was issued pursuant to the Company's 2014 Equity Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on November 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.